Carisma Therapeutics to Present at Upcoming Healthcare Industry Conferences in September 2023
8th Annual CAR-TCR Summit
Michael Klichinsky , PharmD, PhD, Co-Founder and Chief Scientific Officer, will give a presentation during the summit.- "CAR-M: Pioneering a Novel Approach for Solid Tumor Immunotherapy"
Friday, September 1, 2023 at9:20 am ET Boston, Massachusetts
CAR-T Consortia Seminar
Michael Klichinsky , PharmD, PhD, Co-Founder and Chief Scientific Officer, will give a presentation during the meeting.- "CAR Macrophages"
Tuesday, September 19, 2023 at12:00 pm ET - Virtual
A replay of webcasts, when available, will be posted and archived at
About Carisma Therapeutics
Cautionary Note on Forward-Looking Statements
Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute "forward-looking statements" within the meaning of The Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements relating to Carisma Therapeutics' business, strategy, future operations, cash runway, the advancement of Carisma Therapeutics' product candidates and product pipeline, and clinical development of Carisma Therapeutics' product candidates, including expectations regarding timing of initiation and results of clinical trials, and participation by Carisma Therapeutics in future healthcare industry and investor conferences. The words "anticipate," "believe," "contemplate," "continue," "could," "estimate," "expect," "goals," "intend," "may," "might," "outlook," "plan," "project," "potential," "predict," "target," "possible," "will," "would," "could," "should," and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.
Any forward-looking statements are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in, or implied by, such forward-looking statements. For a discussion of these risks and uncertainties, and other important factors, any of which could cause
Media Contact:
(763) 350-5223
jstern@realchemistry.com
Investor Contact:
investors@carismatx.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/carisma-therapeutics-to-present-at-upcoming-healthcare-industry-conferences-in-september-2023-301908583.html
SOURCE